Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.
The antibody-drug conjugate trastuzumab-deruxtecan was associated with high objective response rates among patients with a range of HER2-expressing solid tumors.
CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable
Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.